Indian drug shares declined Wednesday following US President Trump’s tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India’s vital role in supplying affordable medicines to the US.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.